Selective effect of nanostructured preparations on pathogenic bacteria
In the United States, in the framework of the Rapidly Adaptable Nanotherapeutics project, it is planned to develop a new class of antibacterial and antiviral drugs consisting of nanoparticles as a "carrier" and small interfering RNAs (miRNA). Such a genetic construction after introduction into the body will be able to find the cells where the infection develops, and to stop the infectious process.
In the course of experimental and clinical studies of nanostructured preparations, a previously unknown effect of selective action on pathogenic bacteria and the absence of bactericidal action on the intestinal microbiota of the intestine, which fulfills the most important functions in the living body and ultimately determines the health of the organism or its disease, were discovered.
Nanostructural preparations are not antibiotics and do not contain residual amounts of antibiotics, they are not addictive and the population of antibiotic-resistant strains of infectious diseases of the intestine is not formed. Nanostructural drugs are effective in short courses of treatment.
The International academy of authors of scientific discoveries and inventions has recognized the presented materials as a discovery entitled "The phenomenon of selectivity of the effect of nanostructured chemotherapeutic drugs with a tunable nanostructure and a changeable topology of the surface on intestinal pathogens" with a priority on the date of filing application No.A-652 of December 27, 2016.
The discovery refers to medicine and veterinary medicine, namely, to clinical and experimental microbiology, and can be used to create new means of treatment and prevention of systemic bacterial intestinal infections and dysbiosis, while maintaining the qualitative and quantitative composition of the intestinal microbiota. ■